Patents by Inventor Kathy Delaria

Kathy Delaria has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS
    Publication number: 20110183920
    Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
    Type: Application
    Filed: August 25, 2010
    Publication date: July 28, 2011
    Applicant: AEROVANCE, INC.
    Inventors: Clark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-Fun Wong, Adrian Tomkinson, David Boisvert, Elise Burmeister-Getz, Kathy Delaria
  • Modified IL-4 mutein receptor antagonists
    Patent number: 7785580
    Abstract: This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: August 31, 2010
    Assignee: Aerovance, Inc.
    Inventors: Clark Pan, Steve Roczniak, Jeffrey Michael Greve, Stephanie L. Yung, Malinda Longphre, Teresa Mo-Fun Wong, Adrian Tomkinson, David Boisvert, Elise Burmeister-Getz, Kathy Delaria
  • Antibody inhibiting stem cell factor activity and use for treatment of asthma
    Publication number: 20050112698
    Abstract: The present invention provides human antibodies specific for stem cell factor that contain at least one CDR derived from a combinatorial antibody library. The invention also provides pharmaceutical compositions comprising the antibodies and methods of treating asthma. The invention further provides methods of detecting stem cell factor using the antibodies.
    Type: Application
    Filed: June 14, 2004
    Publication date: May 26, 2005
    Inventors: Steven Neben, Toshihiko Takeuchi, Adrian Tomkinson, Kathy Delaria, Kelly Yan, Teresa Wong, Malinda Longphre
  • Protein having proteinase inhibitor activity
    Patent number: 6294648
    Abstract: BTL.009 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase, and chymotrypsin than towards trypsin-like proteinases. BTL.009, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: September 25, 2001
    Assignee: Bayer Corporation
    Inventors: Kathy Delaria, Steve Roczniak, Christopher Davies